Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2013. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
Material Changes
On November 15, 2013, Mr. C Weber, a PDMR, executed the following transactions under the GlaxoSmithKline Share Option Plan (SOP):
- Exercised options for 26,800 shares granted in 2006 at £14.68/share and sold them at £16.09/share.
- Exercised options for 26,800 shares granted in 2007 at £14.88/share and sold them at £16.09/share.
- Exercised options for 36,760 shares granted in 2009 at £11.77/share and sold them at £16.09/share.
- Exercised options for 36,760 shares granted in 2010 at £12.035/share and sold them at £16.08/share.
- Sold 9,065 ordinary shares at £16.0962/share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the total number of shares sold by Mr. C Weber (136,185 shares) against the company's insider trading logs.
- Confirm the market price of GSK shares on November 15, 2013, to validate the sale prices reported (£16.08–£16.0962).
- Review the original grant dates and exercise prices for the 2006, 2007, 2009, and 2010 option tranches to calculate realized gains.
- Check subsequent filings for any additional transactions by Mr. C Weber or other PDMRs.